Molecular Tumor Board-Guided Osimertinib Therapy in EGFR L858R/Q701L-Mutant Lung Adenocarcinoma Supported by Functional Validation.
Functional testing of a rare mutation before treatment enabled an effective therapy decision, demonstrating precision oncology infrastructure value.
Albers-Leischner et al. describe a molecular tumour board-guided case where functional ex vivo validation of osimertinib sensitivity was performed for a novel EGFR L858R/Q701L compound mutation prior to clinical administration, resulting in radiographic treatment response. The case demonstrates the clinical value of integrating precision oncology infrastructure with functional assay validation and MTB governance for rare EGFR variant tumours beyond standard approved indications.
What the study was
- Study design
- Single case report with functional ex vivo validation
- Population
- Patient with EGFR L858R/Q701L compound mutation lung adenocarcinoma
- Sample size
- 1
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Oncologist
Why it surfaced
MTB-guided case with functional validation for novel EGFR compound mutation in The Oncologist; demonstrates precision oncology workflow value.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.